title: [Complex assessment of late side effects affecting quality of life - the "Debrecen model"].
abstract: As the outcome of childhood cancer improved substantially during the last 3 decades, the attitude of pediatric oncology has changed from "cure at any cost" to "cure at least cost". We investigated factors affecting quality of life in long-term survivors of childhood cancer in the in- and outpatient clinics of the Department of Pediatric Hematology-oncology, Institute of Pediatrics, Medical and Health Science Center, Debrecen. As a part of a comprehensive follow-up care program, we focused our attention on nephrotoxicity, osteoporosis and on cardiovascular morbidity. For long-term survivors of childhood cancer sensitive and cost-effective diagnostic algorithms were developed that can help in guiding secondary and tertiary prevention programs, in addition to assessing accurately the condition of patients. We found that anti-cancer treatments, including some of the supportive interventions, have adverse effects on glomerular (10%) and tubular functions (37%), impair the balance of bone resorption and formation (69%) and increase the frequency of cardiovascular risk factors (62%) in a significant proportion of patients. Our data confirm and extend the findings of other investigators and cooperative groups. In conclusion, we consider it important that the treatment plans of high-risk patients with cancer should be aimed at preserving the anticancer potential of therapy, without enhancing the frequency and severity of complications. The presented "Debrecen model" may help in achieving this goal and in increasing quality of life of long-term survivors of childhood cancer.
authors.affiliation: Gyermekhematológiai és Onkológiai Részleg, Markusovszky Kórház, Szombathely, Hungary. editbardi@hotmail.com
authors.forename: Edit
authors.initials: E
authors.lastname: Bárdi
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Jenei
authors.forename: Agnes
authors.initials: A
authors.lastname: Horváth
authors.forename: Tímea
authors.initials: T
authors.lastname: Bodó
authors.forename: Marianna
authors.initials: M
authors.lastname: Bende
authors.forename: Laura
authors.initials: L
authors.lastname: Sándor
authors.forename: Adám
authors.initials: A
authors.lastname: Riz
authors.forename: János
authors.initials: J
authors.lastname: Kappelmayer
authors.forename: Csongor
authors.initials: C
authors.lastname: Kiss
mesh_terms: D000293:Adolescent; D000328:Adult; D000465:Algorithms; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001862:Bone Resorption; D002648:Child; D005260:Female; D005500:Follow-Up Studies; D005919:Glomerular Filtration Rate / Q000187:drug effects*; D006801:Humans; D006814:Hungary; D008297:Male; D009369:Neoplasms / Q000517:prevention & control*; D010012:Osteogenesis / Q000187:drug effects*; D011788:Quality of Life; D055502:Secondary Prevention / Q000379:methods; D017741:Survivors; D055512:Tertiary Prevention / Q000379:methods; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents